1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2018, 68(6):394-424.
2. Ren XC, Liu YE, Li J, Lin Q: Progress in image-guided radiotherapy for the treatment of non-small cell lung cancer. World journal of radiology 2019, 11(3):46-54.
3. Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA: a cancer journal for clinicians 2014, 64(1):9-29.
4. Jenkins BJ: Transcriptional regulation of pattern recognition receptors by Jak/STAT signaling, and the implications for disease pathogenesis. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2014, 34(10):750-758.
5. Kile BT, Alexander WS: The suppressors of cytokine signalling (SOCS). Cellular and molecular life sciences : CMLS 2001, 58(11):1627-1635.
6. Kazi JU, Kabir NN, Flores-Morales A, Rönnstrand L: SOCS proteins in regulation of receptor tyrosine kinase signaling. Cellular and molecular life sciences : CMLS 2014, 71(17):3297-3310.
7. Guo W, Li W, Yuan L, Mei X, Hu W: MicroRNA-106a-3p Induces Apatinib Resistance and Activates Janus-Activated Kinase 2 (JAK2)/Signal Transducer and Activator of Transcription 3 (STAT3) by Targeting the SOCS System in Gastric Cancer. Medical science monitor : international medical journal of experimental and clinical research 2019, 25:10122-10128.
8. Chen M, Zeng J, Chen S, Li J, Wu H, Dong X, Lei Y, Zhi X, Yao L: SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3-mediated blockade of the JAK/STAT3 signaling pathway. Aging 2020, 12(11):10896-10911.
9. Zhang KJ, Tan XL, Guo L: The long non-coding RNA DANCR regulates the inflammatory phenotype of breast cancer cells and promotes breast cancer progression via EZH2-dependent suppression of SOCS3 transcription. Molecular oncology 2020, 14(2):309-328.
10. Li H, Zhang B, Ding M, Lu S, Zhou H, Sun D, Wu G, Gan X: C1QTNF1-AS1 regulates the occurrence and development of hepatocellular carcinoma by regulating miR-221-3p/SOCS3. Hepatology international 2019, 13(3):277-292.
11. Lv Y, Song G, Li P: Correlation of SOCS-1 gene with onset and prognosis of breast cancer. Oncology letters 2018, 16(1):383-387.
12. Sasi W, Jiang WG, Sharma A, Mokbel K: Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer. BMC cancer 2010, 10:178.
13. Li G, Xu J, Wang Z, Yuan Y, Li Y, Cai S, He Y: Low expression of SOCS-1 and SOCS-3 is a poor prognostic indicator for gastric cancer patients. Journal of cancer research and clinical oncology 2015, 141(3):443-452.
14. Sarkozy C, Hung SS, Chavez EA, Duns G, Takata K, Chong LC, Aoki T, Jiang A, Miyata-Takata T, Telenius A et al: Mutational Landscape of Grey Zone Lymphoma. Blood 2020.
15. Zhang J, Meng L, Jiang W, Zhang H, Zhou A, Zeng N: Identification of clinical molecular targets for childhood Burkitt lymphoma. Translational oncology 2020, 13(12):100855.
16. Yang M, Chen H, Zhou L, Huang X, Su F, Wang P: Identification of SOCS family members with prognostic values in human ovarian cancer. American journal of translational research 2020, 12(5):1824-1838.
17. Pasha HF, Mohamed RH, Radwan MI: RASSF1A and SOCS1 genes methylation status as a noninvasive marker for hepatocellular carcinoma. Cancer biomarkers : section A of Disease markers 2019, 24(2):241-247.
18. Martínez-Baños D, Sánchez-Hernández B, Jiménez G, Barrera-Lumbreras G, Barrales-Benítez O: Global methylation and promoter-specific methylation of the P16, SOCS-1, E-cadherin, P73 and SHP-1 genes and their expression in patients with multiple myeloma during active disease and remission. Experimental and therapeutic medicine 2017, 13(5):2442-2450.
19. Kang XC, Chen ML, Yang F, Gao BQ, Yang QH, Zheng WW, Hao S: Promoter methylation and expression of SOCS-1 affect clinical outcome and epithelial-mesenchymal transition in colorectal cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2016, 80:23-29.
20. Culig Z: Suppressors of cytokine signalling-3 and -1 in human carcinogenesis. Frontiers in bioscience (Scholar edition) 2013, 5:277-283.
21. Yoon YH, Hwang HJ, Sung HJ, Heo SH, Kim DS, Hong SH, Lee KH, Cho JY: Upregulation of Complement Factor H by SOCS-1/3⁻STAT4 in Lung Cancer. Cancers 2019, 11(4).
22. Shimada K, Serada S, Fujimoto M, Nomura S, Nakatsuka R, Harada E, Iwahori K, Tachibana I, Takahashi T, Kumanogoh A et al: Molecular mechanism underlying the antiproliferative effect of suppressor of cytokine signaling-1 in non-small-cell lung cancer cells. Cancer science 2013, 104(11):1483-1491.
23. Zhang S, Guo D, Jiang L, Zhang Q, Qiu X, Wang E: SOCS3 inhibiting migration of A549 cells correlates with PYK2 signaling in vitro. BMC cancer 2008, 8:150.
24. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM: ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (New York, NY) 2004, 6(1):1-6.
25. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z: GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic acids research 2017, 45(W1):W98-w102.
26. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science signaling 2013, 6(269):pl1.
27. Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN et al: Visualizing and interpreting cancer genomics data via the Xena platform. Nature biotechnology 2020, 38(6):675-678.
28. Koch A, De Meyer T, Jeschke J, Van Criekinge W: MEXPRESS: visualizing expression, DNA methylation and clinical TCGA data. BMC genomics 2015, 16(1):636.
29. Su LJ, Chang CW, Wu YC, Chen KC, Lin CJ, Liang SC, Lin CH, Whang-Peng J, Hsu SL, Chen CH et al: Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme. BMC genomics 2007, 8:140.
30. Selamat SA, Chung BS, Girard L, Zhang W, Zhang Y, Campan M, Siegmund KD, Koss MN, Hagen JA, Lam WL et al: Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome research 2012, 22(7):1197-1211.
31. Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, Mann FE, Fukuoka J, Hames M, Bergen AW et al: Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PloS one 2008, 3(2):e1651.
32. Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens JA, Hoogsteden HC et al: Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PloS one 2010, 5(4):e10312.
33. Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn PA, Jr., Johnson GL, Hirsch FR, Merrick DT, Franklin WA et al: Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. The American journal of pathology 2005, 167(6):1763-1775.
34. Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R, Furuta K, Tsuta K, Shibata T, Yamamoto S et al: Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer research 2012, 72(1):100-111.
35. Souma Y, Nishida T, Serada S, Iwahori K, Takahashi T, Fujimoto M, Ripley B, Nakajima K, Miyazaki Y, Mori M et al: Antiproliferative effect of SOCS-1 through the suppression of STAT3 and p38 MAPK activation in gastric cancer cells. International journal of cancer 2012, 131(6):1287-1296.
36. Kamizono S, Hanada T, Yasukawa H, Minoguchi S, Kato R, Minoguchi M, Hattori K, Hatakeyama S, Yada M, Morita S et al: The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. The Journal of biological chemistry 2001, 276(16):12530-12538.
37. Linossi EM, Nicholson SE: The SOCS box-adapting proteins for ubiquitination and proteasomal degradation. IUBMB life 2012, 64(4):316-323.
38. Zhang W, Ji W, Zhao X: MiR-155 promotes anaplastic thyroid cancer progression by directly targeting SOCS1. BMC cancer 2019, 19(1):1093.
39. Shayimu P, Wang JB, Liu L, Tuerdi R, Yu CG, Yusufu A: miR-922 regulates apoptosis, migration, and invasion by targeting SOCS1 in gastric cancer. The Kaohsiung journal of medical sciences 2020, 36(3):178-185.
40. Feng S, Wang J, Xu X, Chen X, Luan J, Su Q, Luan M, Wang H, Zhao C: The Expression of SOCS and NF-ϰB p65 in Hypopharyngeal Carcinoma. Iranian journal of public health 2018, 47(12):1874-1882.
41. Ghafouri-Fard S, Oskooei VK, Azari I, Taheri M: Suppressor of cytokine signaling (SOCS) genes are downregulated in breast cancer. World journal of surgical oncology 2018, 16(1):226.
42. Tobelaim WS, Beaurivage C, Champagne A, Pomerleau V, Simoneau A, Chababi W, Yeganeh M, Thibault P, Klinck R, Carrier JC et al: Tumour-promoting role of SOCS1 in colorectal cancer cells. Scientific reports 2015, 5:14301.
43. Ventero MP, Fuentes-Baile M, Quereda C, Perez-Valeciano E, Alenda C, Garcia-Morales P, Esposito D, Dorado P, Manuel Barbera V, Saceda M: Radiotherapy resistance acquisition in Glioblastoma. Role of SOCS1 and SOCS3. PloS one 2019, 14(2):e0212581.
44. Qian Q, Lv Y, Li P: SOCS1 is associated with clinical progression and acts as an oncogenic role in triple-negative breast cancer. IUBMB life 2018, 70(4):320-327.
45. Li F, Hu Q, Pang Z, Xu X: LncRNA MAGI2-AS3 Upregulates Cytokine Signaling 1 by Sponging miR-155 in Non-Small Cell Lung Cancer. Cancer biotherapy & radiopharmaceuticals 2020, 35(1):72-76.
46. Li Z, Metze D, Nashan D, Müller-Tidow C, Serve HL, Poremba C, Luger TA, Böhm M: Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. The Journal of investigative dermatology 2004, 123(4):737-745.
47. Shen G, Shen H, Zhang J, Yan Q, Liu H: DNA methylation in Hepatoblastoma-a literature review. Italian journal of pediatrics 2020, 46(1):113.
48. Gong Y, Wan JH, Zou W, Lian GY, Qin JL, Wang QM: MiR-29a inhibits invasion and metastasis of cervical cancer via modulating methylation of tumor suppressor SOCS1. Future oncology (London, England) 2019, 15(15):1729-1744.
49. Liu M, Cui LH, Li CC, Zhang L: Association of APC, GSTP1 and SOCS1 promoter methylation with the risk of hepatocellular carcinoma: a meta-analysis. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 2015, 24(6):470-483.
50. Shivapurkar N, Stastny V, Suzuki M, Wistuba, II, Li L, Zheng Y, Feng Z, Hol B, Prinsen C, Thunnissen FB et al: Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer letters 2007, 247(1):56-71.
51. Khan MGM, Ghosh A, Variya B, Santharam MA, Ihsan AU, Ramanathan S, Ilangumaran S: Prognostic significance of SOCS1 and SOCS3 tumor suppressors and oncogenic signaling pathway genes in hepatocellular carcinoma. BMC cancer 2020, 20(1):774.
52. Yao Y, Yan Z, Lian S, Wei L, Zhou C, Feng D, Zhang Y, Yang J, Li M, Chen Y: Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma. Journal for immunotherapy of cancer 2020, 8(2).
53. Cui M, Sun J, Hou J, Fang T, Wang X, Ge C, Zhao F, Chen T, Xie H, Cui Y et al: The suppressor of cytokine signaling 2 (SOCS2) inhibits tumor metastasis in hepatocellular carcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2016, 37(10):13521-13531.
54. Letellier E, Schmitz M, Baig K, Beaume N, Schwartz C, Frasquilho S, Antunes L, Marcon N, Nazarov PV, Vallar L et al: Identification of SOCS2 and SOCS6 as biomarkers in human colorectal cancer. British journal of cancer 2014, 111(4):726-735.
55. Haffner MC, Petridou B, Peyrat JP, Révillion F, Müller-Holzner E, Daxenbichler G, Marth C, Doppler W: Favorable prognostic value of SOCS2 and IGF-I in breast cancer. BMC cancer 2007, 7:136.
56. Zhu JG, Dai QS, Han ZD, He HC, Mo RJ, Chen G, Chen YF, Wu YD, Yang SB, Jiang FN et al: Expression of SOCSs in human prostate cancer and their association in prognosis. Molecular and cellular biochemistry 2013, 381(1-2):51-59.
57. Qiu X, Zheng J, Guo X, Gao X, Liu H, Tu Y, Zhang Y: Reduced expression of SOCS2 and SOCS6 in hepatocellular carcinoma correlates with aggressive tumor progression and poor prognosis. Molecular and cellular biochemistry 2013, 378(1-2):99-106.
58. Liu S, Ren S, Howell P, Fodstad O, Riker AI: Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment cell & melanoma research 2008, 21(5):545-558.
59. Sutherland KD, Lindeman GJ, Choong DY, Wittlin S, Brentzell L, Phillips W, Campbell IG, Visvader JE: Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene 2004, 23(46):7726-7733.
60. Li M, Zheng R, Yuan FL: MiR-410 affects the proliferation and apoptosis of lung cancer A549 cells through regulation of SOCS3/JAK-STAT signaling pathway. European review for medical and pharmacological sciences 2018, 22(18):5987-5993.
61. Jiang LH, Hao YL, Zhu JW: Expression and prognostic value of HER-2/neu, STAT3 and SOCS3 in hepatocellular carcinoma. Clinics and research in hepatology and gastroenterology 2019, 43(3):282-291.
62. Zhou QY, Peng PL, Xu YH: MiR-221 affects proliferation and apoptosis of gastric cancer cells through targeting SOCS3. European review for medical and pharmacological sciences 2019, 23(21):9427-9435.
63. Guan HJ, Li XX, Guo YP, Dong J, Rong SZ, Niu YY, Meng LL, Zhao FY, Fan XJ, Zhang YS et al: Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in bladder cancer. International journal of clinical and experimental pathology 2017, 10(11):11326-11334.
64. Zhao R, Chen K, Zhou J, He J, Liu J, Guan P, Li B, Qin Y: The prognostic role of BORIS and SOCS3 in human hepatocellular carcinoma. Medicine 2017, 96(12):e6420.
65. He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello JF, McCormick F, Jablons DM: SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(24):14133-14138.
66. He B, You L, Xu Z, Mazieres J, Lee AY, Jablons DM: Activity of the suppressor of cytokine signaling-3 promoter in human non-small-cell lung cancer. Clinical lung cancer 2004, 5(6):366-370.
67. Liu F, Zhang H, Lu S, Wu Z, Zhou L, Cheng Z, Bai Y, Zhao J, Zhang Q, Mao H: Quantitative assessment of gene promoter methylation in non-small cell lung cancer using methylation-sensitive high-resolution melting. Oncology letters 2018, 15(5):7639-7648.
68. Drilon A, Sugita H, Sima CS, Zauderer M, Rudin CM, Kris MG, Rusch VW, Azzoli CG: A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2014, 9(9):1272-1277.
69. Chen L, Huang X, Zhang W, Liu Y, Chen B, Xiang Y, Zhang R, Zhang M, Feng J, Liu S et al: Correlation of PD-L1 and SOCS3 Co-expression with the Prognosis of Hepatocellular Carcinoma Patients. Journal of Cancer 2020, 11(18):5440-5448.
70. Xu W, Fu J, Wu H, Sun W: Human epidermal growth factor receptor 2 expressions and Janus-activated kinase/signal transducer and activator of transcription 3-suppressor of cytokine signaling 3 pathway may be associated with clinicopathological features and prognosis of gastric cancer. Journal of cancer research and therapeutics 2018, 14(Supplement):S311-s318.
71. Chu Q, Shen D, He L, Wang H, Liu C, Zhang W: Prognostic significance of SOCS3 and its biological function in colorectal cancer. Gene 2017, 627:114-122.
72. Kobayashi D, Nomoto S, Kodera Y, Fujiwara M, Koike M, Nakayama G, Ohashi N, Nakao A: Suppressor of cytokine signaling 4 detected as a novel gastric cancer suppressor gene using double combination array analysis. World journal of surgery 2012, 36(2):362-372.
73. Yoon S, Yi YS, Kim SS, Kim JH, Park WS, Nam SW: SOCS5 and SOCS6 have similar expression patterns in normal and cancer tissues. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2012, 33(1):215-221.
74. Borgés S, Moudilou E, Vouyovitch C, Chiesa J, Lobie P, Mertani H, Raccurt M: Involvement of a JAK/STAT pathway inhibitor: cytokine inducible SH2 containing protein in breast cancer. Advances in experimental medicine and biology 2008, 617:321-329.
75. Zhang MY, Fung TK, Chen FY, Chim CS: Methylation profiling of SOCS1, SOCS2, SOCS3, CISH and SHP1 in Philadelphia-negative myeloproliferative neoplasm. Journal of cellular and molecular medicine 2013, 17(10):1282-1290.
76. Zhang X, Wang J, Cheng J, Ding S, Li M, Sun S, Zhang L, Liu S, Chen X, Zhuang H et al: An integrated analysis of SOCS1 down-regulation in HBV infection-related hepatocellular carcinoma. Journal of viral hepatitis 2014, 21(4):264-271.